Last reviewed · How we verify
Placebo (for Aspirin)
Placebo (for Aspirin) is a Small molecule drug developed by Pharmacoeconomic Unit, Egypt. It is currently FDA-approved for Control comparator in clinical trials (not a therapeutic indication).
Placebo produces no pharmacological effect; therapeutic benefit arises from the placebo effect—patient expectation and psychological factors.
Placebo produces no pharmacological effect; therapeutic benefit arises from the placebo effect—patient expectation and psychological factors. Used for Control comparator in clinical trials (not a therapeutic indication).
At a glance
| Generic name | Placebo (for Aspirin) |
|---|---|
| Sponsor | Pharmacoeconomic Unit, Egypt |
| Modality | Small molecule |
| Therapeutic area | General/Control agent |
| Phase | FDA-approved |
Mechanism of action
Placebo is an inert substance used as a control in clinical trials and sometimes therapeutically to leverage the placebo effect, wherein patient belief in treatment efficacy can produce measurable clinical improvements independent of any active drug mechanism. In this context, it serves as a comparator to aspirin to isolate the true pharmacological benefit of aspirin from psychological and contextual factors.
Approved indications
- Control comparator in clinical trials (not a therapeutic indication)
Common side effects
- Nocebo effects (adverse events attributed to placebo by patient expectation)
Key clinical trials
- IRELAnD: Investigating the Role of Early Low-dose Aspirin in Diabetes (PHASE3)
- Aspirin in Preventing Colorectal Cancer in Patients With Colorectal Adenoma (PHASE2)
- The Impact of Factor Xa Inhibition on Thrombosis, Platelet Activation, and Endothelial Function in Peripheral Artery Disease (PHASE4)
- Aspirin Continuation or Interruption in Patients at Moderate Risk for Cardiovascular Events Undergoing Colonoscopy and/or Polypectomy (PHASE3)
- REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Participants (PHASE3)
- Adjuvant Low Dose Aspirin in Colorectal Cancer (PHASE3)
- Effectiveness of the Eradication of Helicobacter Pylori and an Inhibitor of Pump With Proton Versus Control (PHASE4)
- COLchicine and Non-enteric Coated Aspirin in the Cardiovascular Outcomes Trial of Patients With Type 2 Diabetes (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo (for Aspirin) CI brief — competitive landscape report
- Placebo (for Aspirin) updates RSS · CI watch RSS
- Pharmacoeconomic Unit, Egypt portfolio CI
Frequently asked questions about Placebo (for Aspirin)
What is Placebo (for Aspirin)?
How does Placebo (for Aspirin) work?
What is Placebo (for Aspirin) used for?
Who makes Placebo (for Aspirin)?
What development phase is Placebo (for Aspirin) in?
What are the side effects of Placebo (for Aspirin)?
Related
- Manufacturer: Pharmacoeconomic Unit, Egypt — full pipeline
- Therapeutic area: All drugs in General/Control agent
- Indication: Drugs for Control comparator in clinical trials (not a therapeutic indication)
- Compare: Placebo (for Aspirin) vs similar drugs
- Pricing: Placebo (for Aspirin) cost, discount & access